444 related articles for article (PubMed ID: 2107521)
21. Immunization with Haemophilus influenzae type b polysaccharide vaccine at 18 and 24 months of age: evidence of decreased immunogenicity.
Adderson EE; Chisholm N; Halperin SA
Clin Invest Med; 1991 Aug; 14(4):338-45. PubMed ID: 1782732
[TBL] [Abstract][Full Text] [Related]
22. Persistence of antibody and booster responses to reimmunization with Haemophilus influenzae type b polysaccharide and polysaccharide diphtheria toxoid conjugate vaccines in children initially immunized at 15 to 24 months of age.
Berkowitz CD; Ward JI; Chiu CE; Marcy SM; Gordon L; Hendley JO; Meier K; Marchant CD; McVerry P
Pediatrics; 1990 Mar; 85(3):288-93. PubMed ID: 2304781
[TBL] [Abstract][Full Text] [Related]
23. Effect of Haemophilus influenzae polysaccharide outer membrane protein complex conjugate vaccine on macrophages.
Ambrosino DM; Bolon D; Collard H; Van Etten R; Kanchana MV; Finberg RW
J Immunol; 1992 Dec; 149(12):3978-83. PubMed ID: 1460286
[TBL] [Abstract][Full Text] [Related]
24. Passive immunization for infection with Haemophilus influenzae type b.
Santosham M; Reid R; Letson GW; Wolff MC; Siber G
Pediatrics; 1990 Apr; 85(4 Pt 2):662-6. PubMed ID: 2179857
[TBL] [Abstract][Full Text] [Related]
25. IgG subclass response to immunization with Haemophilus influenzae type b polysaccharide-outer membrane protein conjugate vaccine.
Granoff DM; Weinberg GA; Shackelford PG
Pediatr Res; 1988 Aug; 24(2):180-5. PubMed ID: 3263612
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of Haemophilus influenzae type b conjugate vaccine (PedvaxHIB) in Papua New Guinean children.
Lehmann D; Kakazo M; Yarsley S; Javati A; Taime J; Saleu G; Namuigi P; Alpers MP; Mendelman PM; Staub T
P N G Med J; 1998; 41(3-4):102-11. PubMed ID: 10934551
[TBL] [Abstract][Full Text] [Related]
27. Age-dependent V region expression in the human antibody response to the Haemophilus influenzae type b polysaccharide.
Lucas AH; Azmi FH; Mink CM; Granoff DM
J Immunol; 1993 Mar; 150(5):2056-61. PubMed ID: 8436834
[TBL] [Abstract][Full Text] [Related]
28. Antibody response of Mexican infants to Haemophilus influenzae type b capsular polyribosylribitol phosphate. Differences between natural and vaccine induced (oligosaccharide-CRM197 conjugated vaccine) immunization.
Massó F; Paéz A; Arista A; Salmón L; Montaño L
Arch Med Res; 1996; 27(4):539-45. PubMed ID: 8987192
[TBL] [Abstract][Full Text] [Related]
29. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine.
Munoz A; Salvador A; Brodsky NL; Arbeter AM; Porat R
Pediatrics; 1995 Aug; 96(2 Pt 1):216-9. PubMed ID: 7630672
[TBL] [Abstract][Full Text] [Related]
30. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months.
Madore DV; Johnson CL; Phipps DC; Myers MG; Eby R; Smith DH
Pediatrics; 1990 Oct; 86(4):527-34. PubMed ID: 2216616
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and reactogenicity of four Haemophilus influenzae type b capsular polysaccharide vaccines in Finnish 24-month-old children.
Käyhty H; Peltola H; Eskola J
Pediatr Infect Dis J; 1988 Aug; 7(8):574-7. PubMed ID: 3050853
[TBL] [Abstract][Full Text] [Related]
33. National Advisory Committee on Immunization (NACI). Statement on Haemophilus influenzae type B conjugate vaccines for use in infants and children.
Can Commun Dis Rep; 1992 Dec; 18(23):169-76. PubMed ID: 1291012
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine formulation in healthy adults.
Bulkow LR; McMahon BJ; Wainwright RB; Parkinson AJ; Wainwright KY; House J
Arctic Med Res; 1993 Jul; 52(3):118-26. PubMed ID: 8397580
[TBL] [Abstract][Full Text] [Related]
35. Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody.
Lee YC; Kelly DF; Yu LM; Slack MP; Booy R; Heath PT; Siegrist CA; Moxon RE; Pollard AJ
Clin Infect Dis; 2008 Jan; 46(2):186-92. PubMed ID: 18171249
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity of Haemophilus influenzae type b capsular polysaccharide vaccines in 18-month-old infants.
Hendley JO; Wenzel JG; Ashe KM; Samuelson JS
Pediatrics; 1987 Sep; 80(3):351-4. PubMed ID: 3306597
[TBL] [Abstract][Full Text] [Related]
37. New considerations for Haemophilus influenzae type b vaccination.
Pinson JB; Weart CW
Clin Pharm; 1992 Apr; 11(4):332-6. PubMed ID: 1563228
[TBL] [Abstract][Full Text] [Related]
38. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group.
Schlesinger Y; Granoff DM
JAMA; 1992 Mar; 267(11):1489-94. PubMed ID: 1538539
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide--Neisseria meningitidis outer membrane protein.
Ahonkhai VI; Lukacs LJ; Jonas LC; Calandra GB
Vaccine; 1991 Jun; 9 Suppl():S38-41; discussion S42-3. PubMed ID: 1891956
[TBL] [Abstract][Full Text] [Related]
40. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants.
Granoff DM; Anderson EL; Osterholm MT; Holmes SJ; McHugh JE; Belshe RB; Medley F; Murphy TV
J Pediatr; 1992 Aug; 121(2):187-94. PubMed ID: 1640282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
